<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Febuxostat: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Febuxostat: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Febuxostat: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12173" href="/d/html/12173.html" rel="external">see "Febuxostat: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F52815802"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular death:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Gout patients with established cardiovascular (CV) disease treated with febuxostat had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study. Consider the risks and benefits of febuxostat when deciding to prescribe or continue patients on febuxostat. Febuxostat should only be used in patients who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F7254933"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Uloric</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869029"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AURO-Febuxostat;</li>
<li>JAMP Febuxostat;</li>
<li>MAR-Febuxostat;</li>
<li>TEVA-Febuxostat;</li>
<li>Uloric [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F7258706"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antigout Agent;</li>
<li>
                        Xanthine Oxidase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F7258764"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Urate-lowering therapy (ULT) may be initiated during a gout flare or after the flare subsides; concomitant pharmacologic prophylaxis with colchicine, nonsteroidal anti-inflammatory drugs, or a glucocorticoid is recommended for at least the first 3 to 6 months to decrease flare activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32391934']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32391934'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1ca8c769-43a0-4c93-858f-effa68bd5bc3">Hyperuricemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperuricemia: Oral:</b> Initial: 40 mg once daily; may increase to 80 mg once daily in patients who do not achieve a serum uric acid level &lt;6 mg/dL after 2 weeks. The dose may be increased further to 120 mg once daily if clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27457514']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27457514'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ff53521b-ed4a-44dc-bb5c-9880360bb509">Tumor lysis syndrome, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tumor lysis syndrome, prevention (alternative therapy) (off-label use):</b> Patients at intermediate or high risk for tumor lysis syndrome (TLS):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Aggressive IV hydration should always be initiated prior to cytotoxic therapy in patients at elevated risk for TLS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18509186']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18509186'])">Ref</a></span>). The optimal dose of febuxostat for the prevention of TLS is not yet established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30972811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30972811'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 40 to 60 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sharma.1','lexi-content-ref-25503162','lexi-content-ref-27017611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sharma.1','lexi-content-ref-25503162','lexi-content-ref-27017611'])">Ref</a></span>) <b>or</b> 120 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26216382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26216382'])">Ref</a></span>). Begin 1 to 2 days before the start of chemotherapy and continue for up to 14 days until normalization of laboratory evidence of TLS (eg, serum uric acid, serum lactate dehydrogenase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18509186','lexi-content-ref-Sharma.1','lexi-content-ref-26216382','lexi-content-ref-27017611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18509186','lexi-content-ref-Sharma.1','lexi-content-ref-26216382','lexi-content-ref-27017611'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991926"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Initial: 20 to 40 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>). <b>Note:</b> Observational studies in patients with hyperuricemia have reported safety and tolerability of 60 and 80 mg/day; a careful titration may be considered in patients unresponsive to standard doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30959584','lexi-content-ref-27503183','lexi-content-ref-15662289','lexi-content-ref-26894653','lexi-content-ref-30073793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30959584','lexi-content-ref-27503183','lexi-content-ref-15662289','lexi-content-ref-26894653','lexi-content-ref-30073793'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (highly protein bound): Initial: 20 to 40 mg once daily; no supplemental dose necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32043690','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32043690','lexi-content-ref-Expert.DOR'])">Ref</a></span>). <b>Note:</b> A small, retrospective, observational study in patients with hyperuricemia reported safety and tolerability of doses up to 80 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27503183']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27503183'])">Ref</a></span>); a careful titration may be considered in patients unresponsive to standard doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (highly protein bound): Initial: 20 to 40 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32043690','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32043690','lexi-content-ref-Expert.DOR'])">Ref</a></span>). <b>Note:</b> A small, retrospective, observational study in patients with hyperuricemia reported safety and tolerability of doses up to 80 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27503183']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27503183'])">Ref</a></span>); a careful titration may be considered in patients unresponsive to standard doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Dose as for CrCl &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration</b>
<b>):</b> Dose as for CrCl &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989176"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Preexisting hepatic impairment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">ALT or AST &gt;3 times ULN (in the clinical context of potential liver injury [eg, fatigue, anorexia, right upper quadrant pain, dark urine, jaundice]): Interrupt febuxostat therapy and evaluate. Do not reinitiate febuxostat if liver injury is confirmed or no alternate etiology for liver test abnormalities is identified.</p>
<p style="text-indent:-2em;margin-left:4em;">ALT or AST &gt;3 times ULN <b>and</b> serum total bilirubin &gt;2 times ULN without alternative etiology: Permanently discontinue.</p></div>
<div class="block dot drugH1Div" id="F55701426"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Hypersensitivity or severe skin reactions: Discontinue febuxostat if hypersensitivity or severe skin reactions develop.</p></div>
<div class="block doe drugH1Div" id="F7258765"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F58283203"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute gout attacks</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute gout attacks</b> have been reported during the early stages of urate-lowering therapy, including febuxostat, even when normal or optimal serum uric acid levels have been attained. Gout attacks generally decrease in duration and severity after several months of urate-lowering therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32391934','lexi-content-ref-24758886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32391934','lexi-content-ref-24758886'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action and innate immune response. Decrease in serum urate leads to the dissolution of monosodium urate crystal deposits and dispersion of crystals. Gout flares occur via complement activation and direct interaction of monosodium urate crystals with neutrophils and monocytes/macrophages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24758886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24758886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; most likely to occur within first 6 months of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24758886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24758886'])">Ref</a></span>); risk is lower after 1 year of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27802508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27802508'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Early in course of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18600509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18600509'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Initiating urate-lowering treatment without concurrent gout flare prophylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32391934']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32391934'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Withdrawal of anti-inflammatory gout flare prophylaxis &lt;3 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16339094','lexi-content-ref-18600509','lexi-content-ref-32391934','lexi-content-ref-21353107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16339094','lexi-content-ref-18600509','lexi-content-ref-32391934','lexi-content-ref-21353107'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Uric acid &gt;6 mg/dL during treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16339094','lexi-content-ref-18600509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16339094','lexi-content-ref-18600509'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid decreases and/or greater reduction in uric acid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18600509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18600509'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of tophi (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18600509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18600509'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Delayed hypersensitivity reactions may occur, including morbilliform <b>skin rash</b> and severe cutaneous adverse reactions (SCARs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30690722','lexi-content-ref-25758914','lexi-content-ref-31977653','lexi-content-ref-31308200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30690722','lexi-content-ref-25758914','lexi-content-ref-31977653','lexi-content-ref-31308200'])">Ref</a></span>). SCARs include <b>drug reaction with</b>
<b>eosinophilia and systemic symptoms</b> (DRESS), <b>Stevens-Johnson syndrome</b>, and <b>toxic epidermal necrolysis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22383358','lexi-content-ref-26365588','lexi-content-ref-33021532','lexi-content-ref-30681751','lexi-content-ref-27852432']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22383358','lexi-content-ref-26365588','lexi-content-ref-33021532','lexi-content-ref-30681751','lexi-content-ref-27852432'])">Ref</a></span>). Other delayed reactions include eosinophilic<b> polymyositis </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27955822']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27955822'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Immunologic; delayed hypersensitivity reactions, including morbilliform drug eruptions and SCARs are T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed hypersensitivity reactions: Varied; usually occur within 2 months after initiation with a median of 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30681751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30681751'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between allopurinol and febuxostat: No suspected cross-reactivity based on structural similarity; febuxostat is a non-purine xanthine oxidase inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27667702']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27667702'])">Ref</a></span>). Unlike allopurinol SCAR reactions, there is no known HLA association and no association with HLA-B*58:01 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27667702']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27667702'])">Ref</a></span>). Most patients with a history of a hypersensitivity reaction to allopurinol can tolerate febuxostat (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21724706']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21724706'])">Ref</a></span>). While there may be increased risk of a skin reaction with febuxostat in patients with a history of reactions to allopurinol, the basis of this may not be cross-reactivity. Patients with allopurinol SCAR reactions, such as DRESS, can have relapse of the rash in the absence of the drug following the reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26709250','lexi-content-ref-27667702','lexi-content-ref-32616605']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26709250','lexi-content-ref-27667702','lexi-content-ref-32616605'])">Ref</a></span>). In one study, febuxostat did not differ significantly from allopurinol in the risk of hypersensitivity reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32024648']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32024648'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Major cardiovascular events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Major adverse cardiovascular events (MACE), including cardiovascular death and hospitalizations due to heart failure (HF), have been reported in association with febuxostat (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36035929','lexi-content-ref-35732345','lexi-content-ref-36249825','lexi-content-ref-33181081','lexi-content-ref-31272565','lexi-content-ref-29527974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36035929','lexi-content-ref-35732345','lexi-content-ref-36249825','lexi-content-ref-33181081','lexi-content-ref-31272565','lexi-content-ref-29527974'])">Ref</a></span>). In contrast, other studies have not found an elevated risk of MACE (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32793871','lexi-content-ref-30863448','lexi-content-ref-32801136','lexi-content-ref-34013998','lexi-content-ref-31098635','lexi-content-ref-36317407']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32793871','lexi-content-ref-30863448','lexi-content-ref-32801136','lexi-content-ref-34013998','lexi-content-ref-31098635','lexi-content-ref-36317407'])">Ref</a></span>). Guidelines recommend considering alternative urate-lowering therapy in patients with a history of cardiovascular disease (CVD) or a new CVD-related event (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32390306']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32390306'])">Ref</a></span>). There may be an increased risk of CV events with febuxostat compared to allopurinol; although, some studies show similar risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36437395','lexi-content-ref-35973263','lexi-content-ref-29527974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36437395','lexi-content-ref-35973263','lexi-content-ref-29527974'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; xanthine oxidase inhibition may disrupt the activity of nitric oxide synthase, which can reduce coronary blood flow and cause ineffective excitation contraction myocardial coupling. Additionally, the chemical activities of a non–purine-like medication (febuxostat) compared to a purine analog (allopurinol) may contribute to less cardiovascular (CV) protective effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36035929','lexi-content-ref-30863448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36035929','lexi-content-ref-30863448'])">Ref</a></span>). Rebound hyperuricemia at the time of drug discontinuation may lead to acute inflammation caused by monosodium urate crystals that deposit within the CV system, as well as endothelial dysfunction and oxidative stress (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35732345','lexi-content-ref-34104597']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35732345','lexi-content-ref-34104597'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; may occur at any point during treatment. Increased incidence of CV events, including CV death, have also been observed within 6 months after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29869840','lexi-content-ref-35732345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29869840','lexi-content-ref-35732345'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of CVD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29527974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29527974'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Female patients may have an increased risk of HF hospitalization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36035929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36035929'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Discontinuation of febuxostat; and after discontinuation, fluctuations in uric acid levels, age, and body mass index (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35732345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35732345'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F7258744"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (0.5% to 2%)<span class="lexi-table-link-container"> (<a aria-label="Skin Rash table link" class="lexi-table-link" data-table-id="lexi-content-skin-rash" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-skin-rash')">table 1</a>)</span><span class="table-link" style="display:none;">Skin Rash</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Skin Rash" frame="border" id="lexi-content-skin-rash" rules="all">
<caption style="text-align:center;">
<b>Febuxostat: Adverse Reaction: Skin Rash</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Febuxostat)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Allopurinol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Febuxostat)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Allopurinol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">80 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,279</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,277</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">134</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">40 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">757</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,277</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">134</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic insufficiency (5% to 7%), increased serum alanine aminotransferase (3%), increased serum aspartate aminotransferase (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≤1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris, atrial fibrillation, atrial flutter, chest pain, ECG abnormality, edema, flushing, heart murmur, hypertension, hypotension, increased serum creatine kinase, palpitations, sinus bradycardia, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Abnormal skin odor, alopecia, dermatitis, ecchymoses, eczema, exfoliation of skin, hair discoloration, hyperhidrosis, pruritus, skin discoloration, skin lesion, skin photosensitivity, urticaria (including dermographism)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido, decreased serum bicarbonate, dehydration, diabetes mellitus, gynecomastia, hirsutism, hot flash, hypercholesterolemia, hyperglycemia, hypertriglyceridemia, hypokalemia, increased lactate dehydrogenase, increased LDL cholesterol, increased serum potassium, increased serum sodium, increased thirst, increased thyroid stimulating hormone level, weight gain, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention, abdominal pain, anorexia, cholecystitis, cholelithiasis, constipation, decreased appetite, dysgeusia, dyspepsia, flatulence, frequent bowel movements, gastric hyperacidity, gastritis, gastroesophageal reflux disease, gastrointestinal distress, gingival pain, hematemesis, hematochezia, increased appetite, increased serum amylase, oral mucosa ulcer, pancreatitis, peptic ulcer, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Decreased urine output, erectile dysfunction, hematuria, increased urine output, mastalgia, pollakiuria, prostate specific antigen increase, proteinuria, urinary incontinence, urinary urgency</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, blood coagulation test abnormality, bruise, immune thrombocytopenia, increased MCV, leukocytosis, leukocyturia, leukopenia, lymphocytopenia, neutropenia, pancytopenia, petechia, prolonged partial thromboplastin time, prolonged prothrombin time, purpuric disease, splenomegaly, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, hepatomegaly, increased serum alkaline phosphatase, liver steatosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal electroencephalogram, abnormal gait, agitation, altered sense of smell (decreased), anxiety, asthenia, balance impairment, cerebral infarction (lacunar), cerebrovascular accident, decreased mental acuity, depression, drowsiness, fatigue, feeling abnormal, Guillain-Barré syndrome, headache, hemiparesis, hypertonia, hypoesthesia, insomnia, irritability, lethargy, migraine, myasthenia, nervousness, pain, panic attack, paresthesia, personality changes, transient ischemic attacks, tremor, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis, increased creatine phosphokinase in blood specimen, joint stiffness, joint swelling, muscle rigidity, muscle spasm, muscle twitching, musculoskeletal pain, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Casts in urine, increased blood urea nitrogen, increased serum creatinine, nephrolithiasis, renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis, cough, dry nose, dyspnea, epistaxis, flu-like symptoms, paranasal sinus hypersecretion, pharyngeal edema, respiratory congestion, sneezing, throat irritation, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Mass</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Endocrine &amp; metabolic: Acute gout attack</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, fixed drug eruption (Oda 2016), Stevens-Johnson syndrome, toxic epidermal necrolysis (Han 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Poh 2017), eosinophilia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure, hepatic injury (acute) (Bohm 2016), jaundice (Bohm 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, drug reaction with eosinophilia and systemic symptoms (Paschou 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Psychotic symptoms (including aggressive behavior)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; musculoskeletal: Polymyositis (eosinophilic) (Chahine 2017), rhabdomyolysis (Kang 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis</p></div>
<div class="block coi drugH1Div" id="F7258712"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Concurrent use with azathioprine or mercaptopurine.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Hypersensitivity to febuxostat or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F7258713"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary hyperuricemia: Use in secondary hyperuricemia has not been studied; avoid use in patients at increased risk of urate formation (eg, malignancy and its treatment; Lesch-Nyhan syndrome).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage forms specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: Contains lactose.</p></div>
<div class="block foc drugH1Div" id="F7258774"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Uloric: 40 mg, 80 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg, 80 mg</p></div>
<div class="block geq drugH1Div" id="F7258704"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F7679963"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Febuxostat Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $8.65 - $12.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $8.65 - $12.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Uloric Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $13.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $13.20</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869030"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Uloric: 80 mg [DSC] [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigotine,indigo carmine), quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 80 mg</p></div>
<div class="block adm drugH1Div" id="F7258769"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with or without meals or antacids.</p></div>
<div class="block meg drugH1Div" id="F58283167"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021856s015lbl.pdf%23page%3D19&amp;token=g%2BA54aH4wvzDntmwnWHgdvs9blKdfe305aktcQxXhXYdF608pofddFbTWmFLYWYyA2l5lNVSaReGIrM74NrCveHK45cic%2Fth%2FgfxPgjeWGJPcp%2FTwK%2BTRrm3vj4uowvY&amp;TOPIC_ID=9079" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021856s015lbl.pdf#page=19</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F7258707"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperuricemia:</b> Chronic management of hyperuricemia in patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Not recommended for treatment of asymptomatic hyperuricemia.</p></div>
<div class="block off-label drugH1Div" id="F55701415"><span class="drugH1">Use: Off-Label: Adult</span><p>Tumor lysis syndrome, prevention (alternative therapy)</p></div>
<div class="block cyt drugH1Div" id="F13299314"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C8 (minor), CYP2C9 (minor), UGT1A1, UGT1A3, UGT1A9, UGT2B7; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BCRP/ABCG2</p></div>
<div class="block dri drugH1Div" id="F7273306"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpelisib: BCRP/ABCG2 Inhibitors may increase the serum concentration of Alpelisib.  Management: Avoid coadministration of BCRP/ABCG2 inhibitors and alpelisib due to the potential for increased alpelisib concentrations and toxicities. If coadministration cannot be avoided, closely monitor for increased alpelisib adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">AzaTHIOprine: Febuxostat may increase serum concentrations of the active metabolite(s) of AzaTHIOprine. Febuxostat may increase the serum concentration of AzaTHIOprine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: BCRP/ABCG2 Inhibitors may increase the serum concentration of Berotralstat.  Management: Decrease the berotralstat dose to 110 mg daily when combined with BCRP inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: BCRP/ABCG2 Inhibitors may increase the serum concentration of Cladribine.  Management: Avoid concomitant use of BCRP inhibitors during the 4 to 5 day oral cladribine treatment cycles whenever possible. If combined, consider dose reduction of the BCRP inhibitor and separation in the timing of administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Didanosine: Febuxostat may increase the serum concentration of Didanosine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mercaptopurine: Febuxostat may increase the serum concentration of Mercaptopurine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Febuxostat may enhance the adverse/toxic effect of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: May decrease the serum concentration of UGT1A1 Substrates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: BCRP/ABCG2 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegloticase: Febuxostat may enhance the adverse/toxic effect of Pegloticase. Specifically, Febuxostat may blunt increases in serum urate that would signal an elevated risk of anaphylaxis and infusion reactions. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosuvastatin: Febuxostat may increase the serum concentration of Rosuvastatin.  Management: Limit the dose of rosuvastatin to 20 mg daily when combined with febuxostat. Monitor closely for increased rosuvastatin effects/toxicities (eg, myalgias, rhabdomyolysis) when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: BCRP/ABCG2 Inhibitors may increase the serum concentration of Talazoparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Febuxostat may increase serum concentrations of the active metabolite(s) of Theophylline Derivatives. Specifically, concentrations of 1-methylxanthine, a metabolite of unknown clinical importance, may become elevated. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: BCRP/ABCG2 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: BCRP/ABCG2 Inhibitors may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and second dose (at least 2 hours later if needed) of 50 mg when used with a BCRP inhibitor.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F7258709"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were observed in some animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F16354745"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if febuxostat is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F7258771"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">LFTs at baseline, periodically, and if signs/symptoms of hepatic injury (eg, fatigue, anorexia, right upper quadrant pain, dark urine, jaundice). For gout, monitor serum uric acid levels (as early as 2 weeks after initiation, after each dosage titration), then every 6 months (symptomatic patients or tophi) or every 12 months (all patients on urate-lowering therapy, regardless of symptoms) (FitzGerald 2018). Monitor for signs/symptoms of cardiovascular events and signs/symptoms of hypersensitivity or severe skin reactions.</p></div>
<div class="block rer drugH1Div" id="F7258753"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Uric acid, serum:</p>
<p style="text-indent:-2em;margin-left:2em;">Adults:</p>
<p style="text-indent:-2em;margin-left:4em;">Normal values:</p>
<p style="text-indent:-2em;margin-left:6em;">Males: 3.4 to 7 mg/dL or slightly more</p>
<p style="text-indent:-2em;margin-left:6em;">Females: 2.4 to 6 mg/dL or slightly more</p>
<p style="text-indent:-2em;margin-left:4em;">Goal during therapy: &lt;6 mg/dL; &lt;5 mg/dL in patients with severe gout (eg, tophi, frequent attacks, chronic arthropathy) (EULAR [Richette 2017]). Levels &lt;3 mg/dL are not recommended long-term (EULAR [Richette 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Serum uric acid values &gt;7 mg/dL do not necessarily represent clinical gout; the American College of Rheumatology clinical practice guidelines recommend against initiating pharmacologic management of asymptomatic hyperuricemia (ACR [FitzGerald 2020]).</p></div>
<div class="block pha drugH1Div" id="F7258751"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Selectively inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine to uric acid thereby decreasing uric acid. At therapeutic concentration does not inhibit other enzymes involved in purine and pyrimidine synthesis. </p></div>
<div class="block phk drugH1Div" id="F7258754"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: ≥49%</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>ss</sub>: ~50 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~99%, primarily to albumin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensive conjugation via uridine diphosphate glucuronosyltransferases (UGTs) 1A1, 1A3, 1A9, and 2B7 and oxidation via cytochrome P450 (CYP) 1A2, 2C8, and 2C9 as well as non-P450 enzymes. Oxidation leads to formation of active metabolites (67M-1, 67M-2, 67M-4)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~5 to 8 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 1 to 1.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~49% mostly as metabolites, 3% as unchanged drug); feces (~45% mostly as metabolites, 12% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51154129"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Sex: Following multiple oral doses, C<sub>max</sub> and AUC are 30% and 14% higher in women than men, respectively.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F11390221"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Agout | Donifoxate | Febox | Uloric | Urifox | Zoxta</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Febuloric | Febuxtat</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Feburo | Febuxostat +pharma | Febuxostat accord | Febuxostat aristo | Febuxostat genericon | Febuxostat ratiopharm | Febuxostat sandoz | Febuxostat stada</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Adenuric</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Barif | Eburic | Febulas | Feburic | Febus | Febustat | Febux | Feluric | Fostat | Goustat | Goutil | Uristat | Urostat | Xanuric</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Febuxostat ab | Febuxostat eg | Febuxostat mylan | Febuxostat sandoz</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Druniler | Febustad | Febuxostat mylan | Febuxostat pharmascience | Febuxostat zentiva</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Adenuric</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Feng ding ning | Rui yang</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Febuday</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Febul | Febuxostat accord | Febuxostat krka | Febuxostat msn | Febuxostat mylan | Febuxostat sandoz | Febuxostat zentiva | Urikostad</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Febuxostat 1a pharma | Febuxostat abz | Febuxostat accord | Febuxostat aristo | Febuxostat axiromed | Febuxostat beta | Febuxostat genevida | Febuxostat glenmark | Febuxostat heumann | Febuxostat mylan | Febuxostat ratiopharm | Febuxostat stada | Febuxostat Vivanta | Febuxostat zentiva</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Febuxtat | Staturic</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Druniler | Febuxostat krka | Febuxostat mylan | Febuxostat zentiva</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Andouristat | Donifoxate | Effecturin | Febumagictam | Feburic | Goutifade | Staturic | Unsiatem | Uricodrop | Xanthistop</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Febuxostat aristo | Febuxostat aurovitas | Febuxostat Bluepharma | Febuxostat cinfa | Febuxostat combix | Febuxostat kern pharma | Febuxostat krka | Febuxostat mabo | Febuxostat normon | Febuxostat ratiopharm | Febuxostat sandoz | Febuxostat stada | Febuxostat tecnigen | Febuxostat Teva | Febuxostat Viso farmaceutica | Febuxostat Vivanta | Gotaric</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Febuxostat accord | Febuxostat krka | Febuxostat medical valley</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Febuxostat accord | Febuxostat almus | Febuxostat arrow | Febuxostat biogran | Febuxostat cristers | Febuxostat eg | Febuxostat Evolugen | Febuxostat mylan | Febuxostat sandoz | Febuxostat teva sante | Febuxostat zentiva | Febuxostat zydus</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Febuxostat dr reddys | Febuxostat ennogen</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Buxodem | Febuxostat/genepharm | Urichofeb</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Feburic | Febuxostate pentafarma</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Adenuric</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Doluric | Feburo | Febuxostat krka | Febuxostat sandoz | Febuxostat stada</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Feburic | Ulostat</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Febuxostat accord | Febuxostat clonmel | Febuxostat krka | Febuxostat mylan | Febuxostat pinewood | Febuxostat rowex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Abustat | Arbon | Belosix | Buxoluric | Buxstat | Ciduric | Ebuxo | Fabric | Fabulas | Fabulon | Fabuzest | Factus | Fadvic | Fbt | FBX | Feb | Febiflo | Feboxa | Febric | Febu | Febubest | Febucare | Febucip | Febudim | Febufix | Febuget | Febugood | Febulic | Febumac | Febumost | Febunex | Febupath | Febuplus | Feburic | Febuset | Febusix | Febustat | Febutac | Febutax | Febutaz | Febutek | Febuveda | Febuvel | Febuvib | Febuxoace | Febuxor | Febzeal | Febzen | Fexanto | Fexostat | Forgout | Foxstat | Fubox | Fubra | Furic | Goustat | Goutchek | Goutfree | Goxoi | Ibaxit | Normoric | Sebuxo | Segera | Ubax | Ubexa | Uricheck | Uricostat | Urif | Urifix | Urilact | Urinorm | Uristat | Urixoace | Urostat | Vilstat | X Feb | Xanbit | Xanfeb | Xanthinil | Xanthofex | Xanurix | Zurig</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Alphabux | Arbux | Dymauric | Febuxen | Febuxostat accord | Febuxostat aristo | Febuxostat aurobindo | Febuxostat doc generici | Febuxostat eg | Febuxostat krka | Febuxostat mylan | Febuxostat pensa | Febuxostat sandoz | Febuxostat tecnigen | Febuxostat Teva | Febuxostat zentiva | Gauti | Gottart</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Fixuric | Tazotax | Zoxta</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Feburic | Febuxostat chemiphar | Febuxostat dsep | Febuxostat jg | Febuxostat kyorin | Febuxostat meiji | Febuxostat nipro | Febuxostat nissin | Febuxostat towa</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Feblorika | Febo g | Febuday | Febus | Febustal | Febustat | Febuxo | Fexoberg | Goutgesic | Goutstat | Mebux | Presostat | Theofeb</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dongkoo febuxostat | Fabotat | Febot | Febroct | Febuctam | Feburic | Febuster | Febute | Febuxat | Febuxen | Febuxo | Febuxon | Febuxoric | Febuxsta | Febuxt | Febuxta | Febuxtin | Fecsot | Fegout | Feloxi | Ferad | Ferox | Fesorin | Festa | Fexod | Fexorin | Fexosta | Fexot | Fexotat | Gaobric | Hibric | Inno.n febuxostat | M buric | Nexota | Petrisen | Pharvis febuxostat | Reyon febuxostat | Samsung febuxostat | Seoul febuxostat | Staric | Uburic | Uniferic | Usoric | Yurigat | Yurigout | Yustat</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Agout | Febuxostat biogaran | Oxubat | Staburic</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Druniler | Febuxostat Teva | Febuxostat zentiva</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Febuxostat eg | Febuxostat mylan</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Druniler | Febuxostat krka | Febuxostat mylan | Febuxostat Teva | Febuxostat zentiva</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Uloric</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Turazive</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Febucip | Feburic | Febuton | Goutric | Uloric</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Donifoxate</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Febuxostat accord | Febuxostat Teva | Febuxostat xiromed</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Febuxostat accord | Febuxostat novadoz | Febuxostat sun | Uloric</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Adenuric</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Staturic</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Atenurix | Febsan | Febunol | Feburic | Furic | Mebux | Urica | Urinorm</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Abux | Adenuric | Arrestat | Baristat | Bexol | Biofeb | Burict | Buxo | Buxotat | Degouric | Deliro | Deuric | Dyxostat | Efco | Febex | Febhil | Febo | Feboric | Febstat | Febstate | Febucip | Febugout | Febulos | Febulus | Febunex | Febusave | Febustat | Febusyn | Febux | Febuxin | Frostat | Gouric | Hiloric | Louric | Reduric | Rid uric | Tyloric | Ulora | Uraxat | Urifab | Urifeb | Urigo | Uriguard | Uristat | Urizak | Uromin | Urostat | Vinfebo | Welbux | Welstate | Winstate | Xestat | Xostat | Zerogout | Zurich | Zurig | Zylosat | Zystat</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Denofix | Febuxostat accord | Febuxostat krka | Prohidna</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Uloric</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Febuxostate aristo | Febuxostate bluepharma | Febuxostate farmoz | Febuxostate generis | Febuxostate tolife</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Gouric | Zoxta | Zynostat</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Febuxostat aurobindo | Pexalit</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Azurix</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Agout | Goutex</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Febuxostat accord | Febuxostat krka</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Feburic</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Abuxar | Adenuric | Febuksostat teva</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Abuxar | Adenuric | Febuxostat sandoz</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Feburic</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Adenuric</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Adenuric</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Feburic | Febuton | Fetrin | Feuri | Forliton</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Adenuric | Efstat | Eurofeb | Febuxostat xantis | Liquestia | Podafeb | Podagrat</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Fabutas | Febuday | Febumac | Mebux</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Febuxotid vk | Foribat | Uloxoric | Vaidilox | Vocanz</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adenuric</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Xanurix</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-22383358">
<a name="22383358"></a>Abeles AM. Febuxostat hypersensitivity. <i>J Rheumatol</i>. 2012;39(3):659. doi:10.3899/jrheum.111161<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/22383358/pubmed" id="22383358" target="_blank">22383358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32793871">
<a name="32793871"></a>Al-Abdouh A, Khan SU, Barbarawi M, et al. Effects of febuxostat on mortality and cardiovascular outcomes: a systematic review and meta-analysis of randomized controlled trials. <i>Mayo Clin Proc Innov Qual Outcomes</i>. 2020;4(4):434-442. doi:10.1016/j.mayocpiqo.2020.04.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/32793871/pubmed" id="32793871" target="_blank">32793871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26709250">
<a name="26709250"></a>Bardin T, Chalès G, Pascart T, et al. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. <i>Joint Bone Spine</i>. 2016;83(3):314-317. doi:10.1016/j.jbspin.2015.07.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/26709250/pubmed" id="26709250" target="_blank">26709250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18600509">
<a name="18600509"></a>Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. <i>Nucleosides Nucleotides Nucleic Acids</i>. 2008;27(6):585-591. doi:10.1080/15257770802136032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/18600509/pubmed" id="18600509" target="_blank">18600509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16339094">
<a name="16339094"></a>Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. <i>N Engl J Med</i>. 2005;353(23):2450-2461. doi:10.1056/NEJMoa050373<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/16339094/pubmed" id="16339094" target="_blank">16339094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30972811">
<a name="30972811"></a>Bellos I, Kontzoglou K, Psyrri A, Pergialiotis V. Febuxostat administration for the prevention of tumour lysis syndrome: a meta-analysis. <i>J Clin Pharm Ther.</i> 2019;44(4):525-533. doi:10.1111/jcpt.12839<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/30972811/pubmed" id="30972811" target="_blank">30972811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26679098">
<a name="26679098"></a>Bohm M, Vuppalanchi R, Chalasani N; Drug-Induced Liver Injury Network (DILIN). Febuxostat-induced acute liver injury. <i>Hepatology</i>. 2016;63(3):1047-1049. doi:10.1002/hep.28403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/26679098/pubmed" id="26679098" target="_blank">26679098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17132810">
<a name="17132810"></a>Bruce SP. Febuxostat: A Selective Xanthine Oxidase Inhibitor for the Treatment of Hyperuricemia and Gout. <i>Ann Pharmacother</i>. 2006;40(12):2187-2194.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/17132810/pubmed" id="17132810" target="_blank">17132810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27955822">
<a name="27955822"></a>Chahine G, Saleh K, Ghorra C, Khoury N, Khalife N, Fayad F. Febuxostat-associated eosinophilic polymyositis in marginal zone lymphoma. <i>Joint Bone Spine</i>. 2017;84(2):221-223. doi:10.1016/j.jbspin.2016.10.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/27955822/pubmed" id="27955822" target="_blank">27955822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30690722">
<a name="30690722"></a>Chen CH, Chen CB, Chang CJ, et al. Hypersensitivity and cardiovascular risks related to allopurinol and febuxostat therapy in Asians: a population-based cohort study and meta-analysis. <i>Clin Pharmacol Ther</i>. 2019;106(2):391-401. doi:10.1002/cpt.1377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/30690722/pubmed" id="30690722" target="_blank">30690722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36035929">
<a name="36035929"></a>Cheng CL, Yen CT, Su CC, Lee CH, Huang CH, Yang YK. Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients. <i>Front Cardiovasc Med</i>. 2022;9:891606. doi:10.3389/fcvm.2022.891606<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/36035929/pubmed" id="36035929" target="_blank">36035929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21724706">
<a name="21724706"></a>Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. <i>J Rheumatol</i>. 2011;38(9):1957-1959. doi:10.3899/jrheum.110092<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/21724706/pubmed" id="21724706" target="_blank">21724706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29869840">
<a name="29869840"></a>Choi H, Neogi T, Stamp L, Dalbeth N, Terkeltaub R. New perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated Food and Drug Administration public safety alert. <i>Arthritis Rheumatol</i>. 2018;70(11):1702-1709. doi:10.1002/art.40583<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/29869840/pubmed" id="29869840" target="_blank">29869840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32043690">
<a name="32043690"></a>Choi SY, Choi SW, Lee S, So MW, Oh JS, Lim DH. Efficacy and tolerability of febuxostat in gout patients on dialysis.<i> Intern Med J</i>. 2021;51(3):348-354. doi:10.1111/imj.14776<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/32043690/pubmed" id="32043690" target="_blank">32043690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26365588">
<a name="26365588"></a>Chou HY, Chen CB, Cheng CY, et al. Febuxostat-associated drug reaction with eosinophilia and systemic symptoms (DRESS). <i>J Clin Pharm Ther</i>. 2015;40(6):689-692. doi:10.1111/jcpt.12322<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/26365588/pubmed" id="26365588" target="_blank">26365588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18509186">
<a name="18509186"></a>Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. <i>J Clin Oncol.</i> 2008;26(16):2767-2778. doi:10.1200/JCO.2007.15.0177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/18509186/pubmed" id="18509186" target="_blank">18509186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30863448">
<a name="30863448"></a>Cuenca JA, Balda J, Palacio A, Young L, Pillinger MH, Tamariz L. Febuxostat and cardiovascular events: a systematic review and meta-analysis. <i>Int J Rheumatol</i>. 2019;2019:1076189. doi:10.1155/2019/1076189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/30863448/pubmed" id="30863448" target="_blank">30863448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32801136">
<a name="32801136"></a>Deng H, Zhang BL, Tong JD, Yang XH, Jin HM. Febuxostat use and risks of cardiovascular disease events, cardiac death, and all-cause mortality: metaanalysis of randomized controlled trials. <i>J Rheumatol</i>. 2021;48(7):1082-1089. doi:10.3899/jrheum.200307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/32801136/pubmed" id="32801136" target="_blank">32801136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25758914">
<a name="25758914"></a>Di Paolo C, Minetti S, Mineni M, et al. Desensitization to febuxostat: report of two cases. <i>J Allergy Clin Immunol Pract</i>. 2015;3(4):633-636. doi:10.1016/j.jaip.2015.01.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/25758914/pubmed" id="25758914" target="_blank">25758914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Obesity EditorialTeam: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD,BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32391934">
<a name="32391934"></a>FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. <i>Arthritis Care Res (Hoboken)</i>. 2020;72(6):744-760. doi:10.1002/acr.24180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/32391934/pubmed" id="32391934" target="_blank">32391934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32390306">
<a name="32390306"></a>FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. <i>Arthritis Rheumatol</i>. 2020;72(6):879-895. doi:10.1002/art.41247<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/32390306/pubmed" id="32390306" target="_blank">32390306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29649348">
<a name="29649348"></a>FitzGerald JD, Mikuls TR, Neogi T, et al. Development of the American College of Rheumatology electronic clinical quality measures for gout. <i>Arthritis Care Res (Hoboken)</i>. 2018;70(5):659-671. doi:10.1002/acr.23500<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/29649348/pubmed" id="29649348" target="_blank">29649348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34013998">
<a name="34013998"></a>Gao L, Wang B, Pan Y, Lu Y, Cheng R. Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: a systematic and meta-analysis. <i>Clin Cardiol</i>. 2021;44(7):907-916. doi:10.1002/clc.23643<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/34013998/pubmed" id="34013998" target="_blank">34013998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35732345">
<a name="35732345"></a>Ghang BZ, Lee JS, Choi J, Kim J, Yoo B. Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial. <i>RMD Open</i>. 2022;8(2):e001944. doi:10.1136/rmdopen-2021-001944<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/35732345/pubmed" id="35732345" target="_blank">35732345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36249825">
<a name="36249825"></a>Guan X, Zhang S, Liu J, et al. Cardiovascular safety of febuxostat and allopurinol in patients with gout: a meta-analysis. <i>Front Pharmacol</i>. 2022;13:998441. doi:10.3389/fphar.2022.998441<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/36249825/pubmed" id="36249825" target="_blank">36249825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33021532">
<a name="33021532"></a>Han P, Hu L. Febuxostat-induced toxic epidermal necrolysis. <i>Am J Ther</i>. 2020;10.1097/MJT.0000000000001256. doi:10.1097/MJT.0000000000001256<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/33021532/pubmed" id="33021532" target="_blank">33021532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26183164">
<a name="26183164"></a>Hira D, Chisaki Y, Noda S, et al. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. <i>Pharmacology</i>. 2015;96(1-2):90-98. doi: 10.1159/000434633.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/26183164/pubmed" id="26183164" target="_blank">26183164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36437395">
<a name="36437395"></a>Kang EH. Considerations for choosing first-line urate-lowering treatment in older patients with comorbid conditions. <i>Drugs Aging</i>. 2022;39(12):923-933. doi:10.1007/s40266-022-00986-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/36437395/pubmed" id="36437395" target="_blank">36437395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31098635">
<a name="31098635"></a>Kang EH, Choi HK, Shin A, et al. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study. <i>Rheumatology (Oxford)</i>. 2019;58(12):2122-2129. doi:10.1093/rheumatology/kez189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/31098635/pubmed" id="31098635" target="_blank">31098635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24612195">
<a name="24612195"></a>Kang Y, Kim MJ, Jang HN, et al. Rhabdomyolysis associated with initiation of febuxostat therapy for hyperuricaemia in a patient with chronic kidney disease. <i>J Clin Pharm Ther</i>. 2014;39(3):328-330. doi:10.1111/jcpt.12144<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/24612195/pubmed" id="24612195" target="_blank">24612195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30959584">
<a name="30959584"></a>Kim SH, Lee SY, Kim JM, Son CN. Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis. <i>Korean J Intern Med.</i> 2020;35(4):998-1003. doi:10.3904/kjim.2018.423<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/30959584/pubmed" id="30959584" target="_blank">30959584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31977653">
<a name="31977653"></a>Koenig D, Royer C, Azar A. Successful desensitization to febuxostat in a patient with hypersensitivity to allopurinol and febuxostat and review of the literature. <i>J Clin Rheumatol</i>. 2021;27(8S):S432-S433. doi:10.1097/RHU.0000000000001296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/31977653/pubmed" id="31977653" target="_blank">31977653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24758886">
<a name="24758886"></a>Latourte A, Bardin T, Richette P. Prophylaxis for acute gout flares after initiation of urate-lowering therapy. <i>Rheumatology (Oxford)</i>. 2014;53(11):1920-1926. doi:10.1093/rheumatology/keu157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/24758886/pubmed" id="24758886" target="_blank">24758886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27667702">
<a name="27667702"></a>Lien YH, Logan JL. Cross-reactions between allopurinol and febuxostat. <i>Am J Med</i>. 2017;130(2):e67-e68. doi:10.1016/j.amjmed.2016.08.042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/27667702/pubmed" id="27667702" target="_blank">27667702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27503183">
<a name="27503183"></a>Lim DH, Oh JS, Ahn SM, et al. Febuxostat in hyperuricemic patients with advanced CKD. <i>Am J Kidney Dis.</i> 2016;68(5):819-821. doi:10.1053/j.ajkd.2016.07.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/27503183/pubmed" id="27503183" target="_blank">27503183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30681751">
<a name="30681751"></a>Lin CW, Huang WI, Chao PH, Chen WW, Hsiao FY. Risk of cutaneous adverse reactions associated with allopurinol or febuxostat in real-world patients: a nationwide study. <i>Int J Clin Pract</i>. 2019;73(5):e13316. doi:10.1111/ijcp.13316<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/30681751/pubmed" id="30681751" target="_blank">30681751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33181081">
<a name="33181081"></a>Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. <i>Lancet</i>. 2020;396(10264):1745-1757. doi:10.1016/S0140-6736(20)32234-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/33181081/pubmed" id="33181081" target="_blank">33181081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15662289">
<a name="15662289"></a>Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. <i>Am J Ther.</i> 2005;12(1):22-34. doi:10.1097/00045391-200501000-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/15662289/pubmed" id="15662289" target="_blank">15662289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27211520">
<a name="27211520"></a>Oda T, Sawada Y, Ohmori S, et al. Fixed drug eruption-like macules caused by febuxostat. <i>Eur J Dermatol</i>. 2016;26(4):412-413. doi:10.1684/ejd.2016.2796<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/27211520/pubmed" id="27211520" target="_blank">27211520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27852432">
<a name="27852432"></a>Paschou E, Gavriilaki E, Papaioannou G, Tsompanakou A, Kalaitzoglou A, Sabanis N. Febuxostat hypersensitivity: another cause of DRESS syndrome in chronic kidney disease?. <i>Eur Ann Allergy Clin Immunol</i>. 2016;48(6):251-255.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/27852432/pubmed" id="27852432" target="_blank">27852432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28079821">
<a name="28079821"></a>Poh XE, Lee CT, Pei SN. Febuxostat-induced agranulocytosis in an end-stage renal disease patient: A case report. <i>Medicine (Baltimore)</i>. 2017;96(2):e5863. doi:10.1097/MD.0000000000005863<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/28079821/pubmed" id="28079821" target="_blank">28079821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27802508">
<a name="27802508"></a>Qaseem A, Harris RP, Forciea MA, et al. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. <i>Ann Intern Med</i>. 2017;166(1):58-68. doi:10.7326/M16-0570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/27802508/pubmed" id="27802508" target="_blank">27802508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32616605">
<a name="32616605"></a>Quilis N, Vela P, Blanco Cáceres BA, et al. Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland. <i>Ann Rheum Dis</i>. 2022;81(7):e124. doi:10.1136/annrheumdis-2020-218226<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/32616605/pubmed" id="32616605" target="_blank">32616605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27457514">
<a name="27457514"></a>Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. <i>Ann Rheum Dis</i>. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/27457514/pubmed" id="27457514" target="_blank">27457514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30073793">
<a name="30073793"></a>Saag KG, Becker MA, Whelton A, et al. Efficacy and safety of febuxostat extended and immediate release in patients with gout and renal impairment: a phase III placebo-controlled study. <i>Arthritis Rheumatol</i>. 2019;71(1):143-153. doi:10.1002/art.40685<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/30073793/pubmed" id="30073793" target="_blank">30073793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26894653">
<a name="26894653"></a>Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L. Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment. <i>Arthritis Rheumatol.</i> 2016;68(8):2035-2043. doi:10.1002/art.39654<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/26894653/pubmed" id="26894653" target="_blank">26894653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36317407">
<a name="36317407"></a>Sawada S, Kajiyama K, Shida H, et al. Cardiovascular risk of urate-lowering drugs: a study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan. <i>Clin Transl Sci</i>. 2023;16(2):206-215. doi:10.1111/cts.13439<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/36317407/pubmed" id="36317407" target="_blank">36317407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34104597">
<a name="34104597"></a>Shahin L, Patel KM, Heydari MK, Kesselman MM. Hyperuricemia and cardiovascular risk. <i>Cureus</i>. 2021;13(5):e14855. doi:10.7759/cureus.14855<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/34104597/pubmed" id="34104597" target="_blank">34104597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sharma.1">
<a name="Sharma.1"></a>Sharma R, Abrol D, Deep Singh G, Angurana SL. Febuxostat versus allopurinol for the prevention and treatment of hyperuricemia in chronic myelogenous leukemia with hyperleucocytosis. <i>JK Science</i>. 2016;18(1):12-15.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35973263">
<a name="35973263"></a>Shin A, Choi SR, Han M, et al. Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: update with accumulated use of febuxostat. <i>Semin Arthritis Rheum</i>. 2022;56:152080. doi:10.1016/j.semarthrit.2022.152080<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/35973263/pubmed" id="35973263" target="_blank">35973263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32024648">
<a name="32024648"></a>Singh JA, Cleveland JD. Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data. <i>Ann Rheum Dis</i>. 2020;79(4):529-535. doi:10.1136/annrheumdis-2019-216917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/32024648/pubmed" id="32024648" target="_blank">32024648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23868909">
<a name="23868909"></a>Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. <i>Ann Rheum Dis</i>. 2014;73(2):328-335.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/23868909/pubmed" id="23868909" target="_blank">23868909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26216382">
<a name="26216382"></a>Spina M, Nagy Z, Ribera JM, et al; FLORENCE Study Group. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. <i>Ann Oncol.</i> 2015;26(10):2155-2161. doi:10.1093/annonc/mdv317<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/26216382/pubmed" id="26216382" target="_blank">26216382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31272565">
<a name="31272565"></a>Su CY, Shen LJ, Hsieh SC, Lin LY, Lin FJ. Comparing cardiovascular safety of febuxostat and allopurinol in the real world: a population-based cohort study. <i>Mayo Clin Proc</i>. 2019;94(7):1147-1157. doi:10.1016/j.mayocp.2019.03.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/31272565/pubmed" id="31272565" target="_blank">31272565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25503162">
<a name="25503162"></a>Takai M, Yamauchi T, Ookura M, et al. Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study. <i>Anticancer Res.</i> 2014;34(12):7287-7296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/25503162/pubmed" id="25503162" target="_blank">25503162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27017611">
<a name="27017611"></a>Tamura K, Kawai Y, Kiguchi T, et al. Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. <i>Int J Clin Oncol.</i> 2016;21(5):996-1003. doi:10.1007/s10147-016-0971-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/27017611/pubmed" id="27017611" target="_blank">27017611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31308200">
<a name="31308200"></a>Tana T, Vadas P. Febuxostat desensitization in a patient with previous Stevens-Johnson syndrome and <i>HLA-B*58:01</i> genotype. <i>J Rheumatol</i>. 2019;46(9):1250-1251. doi:10.3899/jrheum.181051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/31308200/pubmed" id="31308200" target="_blank">31308200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Uloric.1">
<a name="Uloric.1"></a>Uloric (febuxostat) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America, Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-UloricCAN.2">
<a name="UloricCAN.2"></a>Uloric (febuxostat) [product monograph]. Oakville, Ontario, Canada: Takeda Canada Inc; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29527974">
<a name="29527974"></a>White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. <i>N Engl J Med</i>. 2018;378(13):1200-1210. doi:10.1056/NEJMoa1710895<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/29527974/pubmed" id="29527974" target="_blank">29527974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21353107">
<a name="21353107"></a>Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. <i>Clin Ther</i>. 2010;32(14):2386-2397. doi:10.1016/j.clinthera.2011.01.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/21353107/pubmed" id="21353107" target="_blank">21353107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16707532">
<a name="16707532"></a>Zhang W, Doherty M, Bardin T, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). <i>Ann Rheum Dis</i>. 2006;65(10):1312-1324.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/febuxostat-drug-information/abstract-text/16707532/pubmed" id="16707532" target="_blank">16707532</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9079 Version 288.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
